<DOC>
	<DOCNO>NCT00094978</DOCNO>
	<brief_summary>This study test safety effectiveness two experimental medicine - depsipeptide flavopiridol - give together treat cancer lung , esophagus , pleura . It determine high dose drug safely give together test whether give together work well shrink tumor give either one alone . Patients 18 year age old cancer lung , esophagus , pleura , cancer spread lung pleura may eligible study . Candidates screen medical history physical examination , blood test , electrocardiogram ( EKG ) , x-rays scan , pulmonary function test , tumor biopsy ( removal small piece tumor tissue microscopic examination ) . Participants admit hospital treatment approximately 10 day 28-day treatment cycle . Depsipeptide infuse arm vein central venous catheter ( tube place large vein neck chest ) 4 hour . When infusion complete , flavopiridol infuse 72 hour . The dose depsipeptide increase four time period study successive group patient , flavopiridol increase determine maximum safe dose give drug together . Blood test do depsipeptide infusion 3 time next 24 hour , various time 4 day flavopiridol infusion evaluate effect medicine . Samples also draw periodically throughout treatment cycle evaluate safety . Heart function monitor several EKGs depsipeptide dos . The drug show effect EKG tracing , appear injure heart muscle . Tumor biopsies do treatment begin fifth day first treatment cycle . The biopsy may do either operate room passing tube ( bronchoscope ) throat lung Radiology Department use thin needle put chest wall tumor . For bronchoscopy , numb medicine spray back throat reduce discomfort , needle biopsy , skin biopsy area numb . Optional repeat biopsy may request start second treatment cycle day 5 cycle . ( The repeat biopsy require participation study . ) At time tumor biopsy , buccal mucosal biopsy also do . This involve scrap tongue depressor along inside mouth collect cell examination . At end first treatment cycle , patient return NIH evaluation physical examination , blood work , x-rays , scans chest , abdomen , pelvis , brain . Patients experience significant drug side effect offer second cycle , exactly like first . The two cycle complete one course treatment , patient return NIH evaluation . Additional treatment cycle may offer patient whose tumor shrink remain stable therapy . Patients whose tumor respond therapy develop severe drug side effect take study .</brief_summary>
	<brief_title>Depsipeptide/Flavopiridol Infusion Cancers Lungs , Esophagus , Pleura , Thymus Mediastinum</brief_title>
	<detailed_description>Background : In preclinical study demonstrate histone deacetylase ( HDAC ) inhibitor Depsipeptide FR901228 ( DP ) mediate cell cycle arrest apoptosis culture lung esophageal cancer , malignant pleural mesothelioma cell . We observe cdk inhibitor Flavopiridol ( FLA ) markedly potentiate Depsipeptide-mediated apoptosis culture cancer cell , culture normal epithelial cell . Patients advanced malignancy involve lung , esophagus , pleura receive 4-hour Depsipeptide infusion follow 72-hour FLA infusion use phase I study design . Tumor buccal mucosa biopsy well PBMC may obtain prior , therapy evaluate gene expression use cDNA array long-oligo protein lysate array technique , determine sequential DP/FLA mediate apoptosis target tissue . Results study may provide rationale phase II evaluation sequential DP/FLA infusion thoracic oncology patient . Objectives : &lt; TAB &gt; Primary objective : To define maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) sequential 4 hour Depsipeptide ( DP ) /72 hour Flavopiridol ( FLA ) To evaluate pharmacokinetics sequential DP/FLA infusion Secondary objective To analyze gene expression profile laser-captured tumor cell , buccal mucosa , PBMC sequential DP/FLA exposure . To analyze mcl-1 protein expression apoptosis tumor biopsy sequential DP/FLA treatment . Tertiary objective : The development tissue serum proteomic technique assess treatment response patient receive sequential DP/FLA infusion . Eligibility : Patients histologically cytologically proven primary small cell non-small cell lung cancer , esophageal cancer , malignant pleural mesothelioma chest wall sarcoma , thymomas eligible evaluation . In addition , patient cancer nonthoracic origin metastasis lung pleura , germ cell tumor refractory standard therapy eligible evaluation . Patients must ECOG performance status 0 - 2 . Patients must adequate pulmonary reserve evidence FEV1 DLCO great 30 percent predict , pCO2 le 50 mm Hg pO2 great 60 mm Hg room air ABG . Patients must 18 year age old . Adequate organ function evidence standard laboratory parameter . The patient must willing sign inform consent . Design : &lt; TAB &gt; &lt; TAB &gt; A phase 1 study patient cohort receive escalate dos Depsipeptide , administer day 1 day 21 , dose flavopiridol ( either 40 mg/m2/d 50 mg/m2/d ) administer day 1-3 , 21-24 42-day course . Pharmacokinetics , systemic toxicity , response therapy record . Two cycle therapy ( one course ) administer , follow treatment evaluation perform use standard clinical criterion . 48 patient enrolled period 2-4 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients histologically cytologically proven small cell nonsmall cell lung cancer , esophageal cancer , malignant pleural mesothelioma chest wall sarcoma , epithelial thymomas eligible evaluation . In addition , patient cancer nonthoracic origin metastasis lung , pleura germ cell tumor refractory standard therapy eligible evaluation . 2 . Chemo naive patient inoperable lung esophageal cancer , pleural mesothelioma , sarcoma , thymomas , well tumor nonthoracic origin metastasis within thorax may eligible study provide apprise , refuse potentially effective first line chemotherapy . 3 . Patients intracranial metastasis treat surgery radiation therapy may eligible study provide evidence active disease requirement anticonvulsant therapy steroid . 4 . Patients prior Depsipeptide Flavopiridol exposure eligible study provide experienced dose limit toxicity dose DP FLA schedule receive . 5 . Patients must chemotherapy , biologic therapy , radiation therapy malignancy least 30 day prior treatment . At least six week must elapse mitomycin C nitrosourea treatment DP/FLA therapy . Patients may receive localized radiation therapy nontarget lesion provide radiotherapy complete 14 day prior commence therapy , patient recover toxicity . 6 . Patients must ECOG performance status 0 2 . 7 . Patients must adequate pulmonary reserve evidence FEV1 DLCO great 30 % predict , pCO2 less 50 mm Hg pO2 great 60 mm Hg room air ABG . 8 . Patients must 18 year age old due unknown effect HDAC inhibitor cdk inhibitor childhood adolescent development . 9 . Patients must platelet count great 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin le 1.5 x upper limit normal , AST/ALT le equal 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . 10 . Patients must aware neoplastic nature his/her illness , experimental nature therapy , alternative treatment , potential benefit , risk . The patient must willing sign inform consent . EXCLUSION CRITERIA : 1 . Patients limited stage SCLC operable NSCLC operable esophageal cancer exclude . 2 . Patients potentially treatable pulmonary metastasis lymphomas germ cell tumor exclude . 3 . Patients receive three systemic cytotoxic treatment regimens exclude due possible cumulative marrow suppression . 4 . Cardiac exclusion criterion , patient know cardiac abnormality : Uncontrolled arrhythmias History serious ventricular arrhythmia control coronary artery bypass surgery . Patients history sustain VT , VF , Toursades de Pointes , cardiac arrest automatic implantable cardioverter defibrillator place . Congenital Long QT syndrome QTc great 480 msec . Patients Mobitz II second degree block pacemaker . Patients cardiac arrhythmia require antiarrhythmic medication beta blocker calcium channel blocker . Patients digitalis discontinue . Decompensated heart failure ( NYHA Class II IV ) . LVEF le 50 % MUGA scan echocardiogram . Hypertrophic restrictive cardiomyopathy prior treatment cause patient leave ventricular hypertrophy . Uncontrolled hypertension ( i.e . great equal to160/95 ) . Myocardial infarction within one year study . Clinically significant active myocardial ischemia basis nuclear image angiography . History coronary artery disease ( e.g . angina Canadian Class IIIV positive stress image study ) . Patients cardiac disease may exclude discretion PI follow consultation cardiology . 5 . Comedication cause QTc prolongation ( information Appendix A http : //georgetowncert.org/gqdrugs_torsades.asp ) unless 5 halflife washout period elapse discontinue drug enter study . 6 . Patients active intracranial leptomeningeal metastasis , well require anticonvulsant medication steroid control cerebral edema exclude . 7 . Patients life expectancy less three month exclude . 8 . Patients pulmonary embolism deep venous thrombosis require anticoagulation within six month protocol entry exclude . 9 . Pregnant patient nurse mother exclude due unknown , potentially harmful effect HDAC inhibitor cdk inhibitor fetal early childhood development . 10 . Patients active infection exclude . 11 . Patients HIV infection exclude due potential risk opportunistic infection DP/FLAinduced myelosuppression potentially deleterious activation viral gene expression . 12 . Patients screen 12 lead EKG patient leave ventricular hypertrophy eligible . 13 . Patients take hydrochlorothiazide ( HCTZ ) agent stop switch potassiumconserving combination ( e.g . Maxide Dyazide ) antihypertensive agent . Patients , agent stop switch potassiumconserving combination antihypertensive agent , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 20, 2013</verification_date>
	<keyword>Apoptosis</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Gene Induction</keyword>
	<keyword>Maximally Tolerated Dose</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>SCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Pleural Mesothelioma</keyword>
</DOC>